Advertisements

Эмоксипин

Quick links to important sections

Эмоксипин

Selected form

Advertisements
Advertisements

Method of action: Retinoprotective

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Эмоксипин

What is Эмоксипин? Overview and Quick Facts

Property Description
Active ingredient Methyl-ethyl-pyridinol succinate (INN)
Common Form Sterile Solution for Injection / Ophthalmic Solution (Eye Drops)
Pharmacological Class Antioxidant, Anti-hypoxant, Membrane Stabilizer
Origin Synthetic Compound (3-Hydroxypyridine Derivative)

Эмоксипин is a highly specialized, synthetic drug widely utilized for its unique protective properties, particularly in vascular and neurological support. Its active ingredient, Methyl-ethyl-pyridinol succinate, is a derivative of 3-hydroxypyridine combined with the metabolic regulator succinate. This structure is chemically designed to inhibit free radical processes and counteract damage from low-oxygen conditions (anti-hypoxic effect). This pharmacological classification confirms the medicine's role in shielding cells from oxidative stress.

This substance belongs to the pharmacological classes of anti-hypoxants and membrane stabilizers. The succinate component is a differentiating feature, recognized for providing an energy substrate that assists cellular resilience under stress. The medicine is commonly provided in sterile liquid forms, including solutions for injection and eye drops, allowing for precise delivery, particularly in ophthalmology where it offers a broad range of protective effects.

What is the General Therapeutic Purpose?

The general purpose of Эмоксипин is to act as a tissue protector by stabilizing cell structures and mitigating damage from free radicals. Pharmacological studies support its effectiveness in supporting microcirculation and general cellular health in conditions where vascular stability is compromised. This action is crucial for preserving the integrity of biological barriers and the function of vulnerable tissues under stress.

Advertisements

What side effects are possible with Эмоксипин?

Possible Side Effects and Safety Information

The safety profile for Methyl-ethyl-pyridinol succinate (Эмоксипин) is established through regulatory classification, which formally groups documented adverse reactions by frequency and affected physiological system. The safety data distinguishes between common, generally transient effects and high-level constraints on use.

Documented Adverse Reactions

Adverse reactions are reported according to standard regulatory frequency categories:

  • Common Reactions may include drowsiness, dry mouth, and nausea. These frequently reported effects are generally related to the Gastrointestinal or Nervous System Disorders.
  • Uncommon/Rare Reactions include significant Blood Pressure Changes (increase or decrease) and Allergic Reactions (such as rash or urticaria). A transient feeling of heat (flushing) is also documented, often noted as being more common at the beginning of treatment.
  • Local Reactions at the administration site, such as a burning sensation or local discomfort, are specific to the injectable form.

Safety Constraints and Special Populations

Official regulatory documents specify explicit conditions where the medicine should not be used (Contraindications). These constraints apply to individuals with known Hypersensitivity to the active substance or excipients, and those diagnosed with Severe Hepatic Impairment or Severe Renal Impairment. Use during pregnancy and lactation is generally restricted due to insufficient regulatory safety data.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Эмоксипин (Methyl-ethyl-pyridinol succinate) overdose is derived exclusively from the specific manifestations documented in official prescribing information and the mandated emergency response. This information strictly adheres to government guidelines on recognized clinical signs and necessary actions.

Documented Manifestations

Overdose scenarios primarily involve Central Nervous System (CNS) effects. The formally documented clinical presentations of an excessive intake are drowsiness (somnolence) and insomnia. Severe or life-threatening outcomes, such as major cardiovascular or respiratory complications, are not explicitly documented in the official overdose sections, reflecting a regulatory assessment of low acute toxicity based on reported data.


Required Emergency Actions

Official regulatory guidelines confirm that no specific antidote is known for the reversal of Эмоксипин's effects. Consequently, the mandated management is defined as symptomatic and supportive treatment, focusing solely on addressing the observed manifestations if they occur. The regulatory instructions require that individuals seek immediate medical attention or consult a healthcare professional upon any suspicion of overdose or administration exceeding the prescribed amount. No specific requirements for hospital monitoring or population-related factors concerning overdose severity are explicitly documented in the official regulatory text regarding emergency procedures.

Advertisements

Therapeutic Uses of Эмоксипин

What Эмоксипин Treats: Main Uses and Benefits

Supporting Symptoms of Ocular Discomfort and Strain

Emoxypine is applied across domains where additional symptomatic support is needed, particularly for managing symptoms linked to organ-specific functional stress, such as feelings of irritation, fatigue, or strain that interfere with daily comfort. This application supports general well-being during symptomatic phases in the ocular area.


Assistance in Managing Systemic and Physiological Strain

The compound is commonly used across conditions characterized by periods of heightened symptoms involving temporary physiological imbalance or stress. For instance, clinical investigations often explore its role as an adjuvant in supportive management for neurological rehabilitation. Indications for use frequently involve contexts presenting with symptoms related to systemic imbalance, neurological activity, and functional stress. It provides support that helps ease the overall symptom burden and supports general well-being during difficult episodes.

Quick Fact: Support for Physiological Strain


Relevant for Managing Acute or Disruptive Episodes

Эмоксипин is considered relevant in contexts involving symptoms associated with acute or episodic changes and heightened physiological tension. The goal in these clinical scenarios is to provide temporary assistance in symptom stabilization. The medicine is applied when symptoms create noticeable physiological strain, helping to address symptom clusters that may become intense or disruptive, and is commonly used when short-term symptomatic assistance is needed to cope more steadily.

“The product is primarily applied when symptoms become more noticeable and require supportive, short-term relief in various clinical settings.”

Advertisements

Eligibility and Restrictions for Use

The official regulatory documentation for Эмоксипин (Methyl-ethyl-pyridinol succinate) defines specific patient populations that are eligible or excluded from use.

Contraindicated Populations

Use is prohibited for groups where safety has not been established or where the risk of adverse effects is high, including:

  • Hypersensitivity: Patients with known intolerance to the active substance or its excipients.
  • Acute Renal Failure: Patients experiencing acute kidney dysfunction.
  • Acute Hepatic Failure: Patients experiencing acute liver dysfunction.
  • Age Restriction: Children and adolescents under 18 years of age due to insufficient data.
  • Pregnancy and Lactation: Use is contraindicated during both pregnancy and breastfeeding due to a lack of established safety data in these populations.

Age- and Condition-Based Eligibility

  • Adult Use: The medicine is established for use in adults (typically 18 years and older).
  • High Blood Pressure: Conditional use applies to patients with severe arterial hypertension (AP gt 180/100 mmHg), requiring close medical monitoring.
  • Organ Function: Severe, acute renal or hepatic failure represents an absolute contraindication, reflecting regulatory caution regarding the drug's metabolism and clearance.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory analysis of the official prescribing information for Эмоксипин (Methyl-ethyl-pyridinol succinate), as published by major international government health authorities, indicates that the product's interaction profile is characterized by the absence of specific, formally documented restrictions.

Official Interaction Statements

The public-facing regulatory documents do not define mandatory constraints concerning co-administration. This includes the following key areas of interaction:

  • Contraindicated Combinations: No specific medicinal products or product classes are formally designated as contraindicated based on established interaction risks.
  • Pharmacokinetic Interactions: No specific patterns of drug metabolism (e.g., CYP enzyme inhibition or induction) or drug transport interactions are officially listed as requiring restriction.
  • Pharmacodynamic Interactions: No official label statements detail specific additive or synergistic effects with other drugs that would necessitate mandatory co-administration restrictions.
  • Timing and Restrictions: No mandatory time-separation or dose-spacing requirements are documented in the official prescribing information.

Connection to the overall interaction profile: The regulatory structure for Эмоксипин is defined by this absence of explicit entries in the official interaction sections of government documents. Consequently, no formally established interaction patterns requiring specific classification (e.g., major, contraindicated) or prescriptive management (e.g., dose separation) are currently stated in the available official documentation.

Advertisements

Mechanism of Action

️ Antioxidant Cytoprotection and Membrane Stabilization

This primary action involves the free radical scavenging and inhibition of Lipid Peroxidation (LPO) by the hydroxypyridine core, directly fortifying the phospholipid bilayer of cells. This structural stabilization increases the cellular tolerance of tissues against chemical and physical stressors.

Dual-Action Bioenergetic and Anti-Hypoxic Support

The molecule provides a dual defense, synergistically combining the membrane protection with an anti-hypoxic mechanism. The succinate moiety acts as a metabolic substrate, activating Mitochondrial Complex II (SDH) to maintain the rate of ATP synthesis during low-oxygen conditions, which contributes to increased tissue tolerance to ischemia.

Neuro-Membranotropic and Vascular Modulation

The stabilization of cell membranes extends to specialized systems, regulating the function of GABAergic and Cholinergic neuronal receptors, which modulates the stability of nerve signaling. In the circulatory system, this action enhances vascular endothelial integrity and reduces platelet aggregation, resulting in support for microcirculation and optimal capillary blood flow dynamics.

Advertisements

Dosage and Administration Information

Administration Guidelines for Эмоксипин

The usage of Эмоксипин (Methyl-ethyl-pyridinol succinate) is structured by standard protocols detailing its administration route, dosing, and procedural requirements. The medicine is used across multiple dosage forms, including sterile solution for injection, oral tablets, and a specialized ophthalmic solution.


Administration Scope

Entity Description
Route of Administration Intravenous (IV), Intramuscular (IM), Oral (Tablet), and Ocular (Topical Drops; Subconjunctival/Parabulbar Injection).
Standard Dosing Parenteral: Initial daily doses are often 500 mg once daily. Oral: Maintenance doses typically range from 250 mg to 750 mg per day, administered in divided doses. The absolute maximum daily dose for systemic use is 1200 mg.
Preparation The injectable solution must be diluted for IV infusion, typically in 0.9% Sodium Chloride. Ampoules are for single use only and must be used immediately upon opening.
Age Restriction Use is restricted to the adult population (18 years of age and older).

Procedural Context and Schedule

Established protocols define a multi-phase regimen, typically beginning with a short-term parenteral course (e.g., 10 to 14 days IV or IM) followed by a longer-term oral maintenance phase. For proper delivery, IV administration is performed as a slow stream or slow infusion (40 to 60 drops per minute). When discontinuing prolonged oral therapy, the dose is gradually reduced over 2 to 3 days.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Эмоксипин

This overview summarizes the research that has been conducted on the medicine, focusing only on the types of studies that exist and what they have examined, without offering any clinical advice or interpretation of the results.


Evidence for Use in Ocular Conditions and Stress

Research has been conducted using Эмоксипин eye drops in studies exploring how symptoms change over time in conditions characterized by functional limitations in the eye. These short-term Randomized Controlled Trials (RCTs) were applied in studies examining patient-reported experiences in adults with chronic conditions, such as specific stages of primary open-angle glaucoma or diabetic retinopathy. The research primarily examined measurements related to specific biochemical markers and measured retinal and visual parameters within the eye.

Studies monitored how measured parameters changed in the observed populations over defined time intervals, typically ranging from a few weeks up to three months. The research describes assessments of visual field parameters and the function of the optic nerve that were measured during the study period. Findings describe patterns observed in the studies, including measurements of specific biochemical markers, such as total antioxidant capacity and lipid peroxidation products.

Evidence for Use in Systemic and Neurological Support

Эмоксипин, in its injectable and solution forms, was studied in research contexts exploring acute and chronic conditions involving periods of heightened symptoms related to systemic or neurological function. The evidence base includes a number of Randomized Controlled Trials (RCTs) and systematic reviews, primarily conducted on adults in the acute or early recovery phase following events like ischemic stroke, or those with chronic cerebral ischemia.

These trials research examined outcomes reflecting daily functioning or activity level, particularly in neurological and cognitive areas. Studies monitored patient-reported outcomes describing perceived discomfort and used standardized scales to evaluate changes in neurological deficits and functional status. Reported findings describe patterns related to short-term changes that were observed in the studies during the treatment and immediate follow-up period.

Research Gaps and Uncertainties

The evidence landscape for Эмоксипин has been studied for specific applications, but key limitations remain. The sample sizes were modest in many trials, and study design and patient groups differ across studies due to heterogeneity. Because a large portion of the research is regional, comparative evidence is lacking in the context of major international guidelines, and high-level systematic reviews from bodies like Cochrane are not widely available to synthesize the findings across all indications. This means that while research has explored short-term changes, the certainty remains low regarding broad, consistent functional outcomes, and long-term effects are not fully established.

Key Studies & References

  1. Efficacy and Safety of Different Dosages of Mexidol® in Patients With Primary Open-angle Glaucoma (POAG) (NCT06903156)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Эмоксипин (FAQ)


Q: Can Эмоксипин make a person feel sleepy or groggy?

According to the official safety profile, drowsiness is listed as a common adverse reaction associated with the medicine. This is a central nervous system (CNS) related effect. Drowsiness is part of the common documented side effect profile.

Q: Is there any information about Эмоксипин's effect on memory or concentration?

The research evidence overview provided by official sources indicates that studies have examined changes in patient outcomes related to neurological deficits and cognitive function. This type of research monitors how these parameters change during the course of the study.

Q: Can Эмоксипин affect my sleep patterns, making it harder or easier to sleep?

The documented adverse reactions include drowsiness as a common effect. Apart from this, official documentation does not generally define specific effects on overall sleep patterns, such as insomnia or sleep facilitation.

Q: Is Эмоксипин the same type of medicine as mild tranquilizers?

No. The official pharmacological classification defines this medicine as an antioxidant, anti-hypoxant, and membrane stabilizer. This classification relates to its ability to protect cells from oxidative stress and low-oxygen conditions.

Q: If I stop taking Эмоксипин suddenly, will I have withdrawal effects?

Official administration instructions state that when discontinuing prolonged oral therapy, the dose is to be gradually reduced over a period of two to three days. This procedure is defined in the official use summaries.

Q: Can Эмоксипин be used long-term, or is it only for short periods?

Official use protocols describe a multi-phase regimen that typically begins with a short-term course (such as the parenteral form) followed by a longer-term oral maintenance regimen. The treatment protocol includes a longer-term oral regimen, but the full duration is determined within the prescribing context.

Q: Are there common feelings or sensations that are considered normal when starting Эмоксипин?

Official safety information documents a transient feeling of heat (flushing) as an uncommon reaction. This sensation is sometimes specifically noted as being more common at the beginning of treatment.

Q: Is it safe to drink coffee or caffeine while taking Эмоксипин?

Official regulatory documents for the medicine do not define mandatory constraints or restrictions concerning the co-administration of caffeine or coffee. The general interaction profile is characterized by the absence of specific, formally documented restrictions.

Q: Are there any known issues with taking Эмоксипин and common pain relievers like ibuprofen?

Official regulatory documents state that no specific medicinal products or product classes, including common pain relievers, are formally designated as contraindicated. The official interaction profile does not list restrictions on co-administration with these drugs.

Q: Are there any specific foods or supplements that should be avoided with Эмоксипин?

Official regulatory documents do not define mandatory constraints concerning the co-administration of specific foods or supplements. The official interaction profile is defined by the absence of mandatory restrictions on foods or supplements.

Q: Is there any research looking into Эмоксипин's role in stress or anxiety relief?

The summarized research evidence provided by official sources focuses on studies examining ocular conditions and outcomes related to neurological deficits and functional status in contexts like acute ischemia. The research summaries do not explicitly detail studies focused on general stress or anxiety relief.

Q: Do studies suggest that Эмоксипин works better in certain age groups?

The research evidence describes studies conducted on adults, typically 18 years and older. However, the available summaries do not contain findings that specifically compare efficacy or suggest preferential use in one adult age group over another.

Q: Does Эмоксипин interact with common medications for high cholesterol?

Official regulatory documents state that no specific medicinal products or product classes (including those used for high cholesterol) are formally designated as contraindicated based on established interaction risks.

Q: How does Эмоксипин affect the central nervous system according to official descriptions?

The official description includes a neuro-membranotropic action, which involves the regulation of specialized neuronal receptors (GABAergic and Cholinergic). This mechanism supports the modulation of nerve signaling stability in the central nervous system.

Q: Is there a maximum length of time Эмоксипин is studied for continuous use?

The research documentation notes that while studies have examined short-term changes, the long-term effects are not fully established. The overview of research evidence notes this as a current limitation.

Q: If I am taking vitamins, is there a risk of interaction with Эмоксипин?

Official regulatory documents do not define mandatory constraints or restrictions concerning the co-administration of vitamins. The overall interaction profile does not list vitamins as a category requiring specific restriction.

Q: Do regulatory bodies list any specific warnings about using Эмоксипин while driving?

The official safety profile includes drowsiness as a common adverse reaction, which is a CNS effect documented in the official information.

Q: Can Эмоксипин be taken alongside herbal supplements like St. John's Wort?

Official regulatory documents state that no specific medicinal products or product classes, including herbal supplements, are formally designated as contraindicated. The documentation is defined by the absence of explicit restrictions.

Q: Does research clarify if the benefits of Эмоксипин are maintained after stopping treatment?

Research evidence primarily focuses on short-term changes observed during the treatment and immediate follow-up period. Because the overview of research notes that long-term effects are not fully established, the long-term maintenance of benefits is not definitively clarified.

Q: Are there any special considerations for people with diabetes using Эмоксипин?

Safety constraints explicitly list severe hepatic (liver) and renal impairment (kidney) as absolute contraindications. Specific general considerations for people with diabetes are not listed in the provided safety constraints.

Q: Does Эмоксипин interact with common birth control medications?

Official regulatory documents state that no specific medicinal products or product classes, including hormonal contraceptives, are formally designated as contraindicated. The interaction section is defined by the absence of explicit restrictions.

Advertisements

How should Эмоксипин be stored and disposed of?

How to Store and Dispose of Эмоксипин

Official regulatory guidelines define strict environmental and container requirements to maintain the stability of Эмоксипин.

Storage Requirements

Condition Requirement
Temperature Store in a cool area, with the recommended temperature for the sealed substance being 4 C.
Protection The product must be stored in a dry, well-ventilated area, protected from direct sunlight and moisture.
Container The container must be kept tightly sealed to maintain product integrity and prevent environmental exposure.

The substance is chemically stable for up to 2 years when stored under these defined, cool, and protected conditions.

Disposal Instructions

Disposal of unused or expired product must be carried out in accordance with all local and governmental regulations for pharmaceutical waste. The official guidance specifically prohibits discarding the product into drains, water courses, or soil to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Эмоксипин found in:

A-Z Index: